BridgeBio to Present Cardiovascular Outcomes Data in Patients with Variant and Wild-type Transthyretin Amyloid Cardiomyopathy (ATTR-CM) from the ATTRibute-CM Study at the ACC Annual Scientific Sessions

Rhea-AI Summary

BridgeBio Pharma (Nasdaq: BBIO) has announced the presentation of cardiovascular outcomes data from their ATTRibute-CM Phase 3 study of acoramidis in ATTR-CM at the upcoming American College of Cardiology (ACC) Annual Scientific Sessions in Chicago, March 29-31, 2025.

The company will present seven studies, including five flatboard poster presentations and two moderated posters, focusing on various aspects of acoramidis treatment in ATTR-CM patients. Key presentations include:

• Acoramidis's impact on serum TTR levels in wild-type and variant ATTR-CM patients
• Improvements in NYHA Class at Month 30 versus placebo
• Effects of combining acoramidis with tafamidis
• Primary endpoint efficacy results and NT-proBNP sensitivity analyses
• Relationship between early serum transthyretin increase and reduced cardiovascular hospitalizations
• Geographic healthcare disparities in ATTR-CM diagnosis

News Market Reaction

+7.05%

1 alert

+7.05% News Effect

On the day this news was published, BBIO gained 7.05%, reflecting a notable positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

PALO ALTO, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announced today that cardiovascular outcomes data in patients with variant and wild-type ATTR-CM from the ATTRibute-CM, its Phase 3 study of acoramidis in ATTR-CM, will be shared in a flatboard poster presentation at the American College of Cardiology (ACC) Annual Scientific Sessions & Expo, taking place in Chicago, Illinois on March 29-31, 2025. Additionally, BridgeBio was selected to share five poster presentations and two moderated posters on ATTR-CM.

Flatboard Poster Presentations:
Acoramidis Improves Serum TTR Levels in Patients with Wild-type or Variant Transthyretin Amyloid Cardiomyopathy
Presenter: Margot Davis, M.D. of Vancouver General Hospital, CA
Date: Monday, March 31 at 9:00 am CT/10:00 am ET

Acoramidis Improves NYHA Class at Month 30 Versus Placebo in Patients with ATTR-CM: Results from the ATTRibute-CM Study
Presenter: Kevin Alexander, M.D. of Stanford University School of Medicine, USA
Date: Sunday, March 30 at 1:30 pm CT/2:30 pm ET

In Participants Treated with Acoramidis, Addition of Concomitant Tafamidis Did Not Further Increase Serum TTR Levels
Presenter: Mathew Maurer, M.D. of Columbia University Irving Medical Center, USA
Date: Monday, March 31 at 9:00 am CT/10:00 am ET

Robustness of Primary Endpoint Efficacy Results with Acoramidis in ATTR-CM in the ATTRibute-CM Study: Pre-specified NT-proBNP Sensitivity Analyses
Presenter: Jan Griffin, M.D. of Medical University of South Carolina, USA
Date: Sunday, March 30 at 1:30 pm CT/2:30 pm ET

Acoramidis-mediated Early Increase in Serum Transthyretin Level Reduces Cardiovascular-related Hospitalizations and Mortality: Insights from the ATTRibute-CM Study
Presenter: Nitasha Sirwat, M.D. of UChicago Medicine, USA
Date: Monday, March 31 at 9:00 am CT/10:00 am ET

Moderated Posters:
Primary Endpoint Efficacy Results in the ATTRibute-CM Study: Pre-specified Sensitivity Analyses Addressed Tafamidis Use
Presenter: Daniel P. Judge, M.D. of Medical University of South Carolina, USA
Date: Saturday, March 29 at 10:06 am CT/11:06 am ET

Geographic Healthcare Disparities and Diagnostic Trends Among Patients with Transthyretin Amyloid Cardiomyopathy
Presenter: Joshua Mitchell, M.D., Washington University School of Medicine in St. Louis, USA
Date: Saturday, March 29 at 10:54 am CT/11:54 am CT

About Attruby™ (acoramidis)
Attruby is the first near-complete (≥90%) stabilizer of Transthyretin (TTR) approved in the U.S. for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular death and cardiovascular-related hospitalization. Attruby was generally well-tolerated. The most common side effects were mild and included diarrhea and abdominal pain that were resolved without drug discontinuation. BridgeBio offers an extensive suite of programs to help patients access our medicines.

About BridgeBio
BridgeBio Pharma (BridgeBio) is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio’s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit bridgebio.com and follow us on LinkedIn, Twitter and Facebook.

BridgeBio Media Contact:
Bubba Murarka, EVP Communications
contact@bridgebio.com
(650)-789-8220

FAQ

What are the key findings of BridgeBio's (BBIO) ATTRibute-CM Phase 3 study being presented at ACC 2025?

The study shows acoramidis improves serum TTR levels, NYHA Class at Month 30 vs placebo, and reduces cardiovascular-related hospitalizations and mortality in ATTR-CM patients.

When and where will BridgeBio (BBIO) present its ATTRibute-CM study results?

BridgeBio will present at the ACC Annual Scientific Sessions in Chicago, Illinois, from March 29-31, 2025.

How many presentations will BridgeBio (BBIO) deliver at ACC 2025 regarding acoramidis?

BridgeBio will deliver seven presentations: five flatboard poster presentations and two moderated posters on ATTR-CM and acoramidis.

What is the interaction between acoramidis and tafamidis in BBIO's ATTRibute-CM study?

The study found that adding concomitant tafamidis to acoramidis treatment did not further increase serum TTR levels in participants.

How does acoramidis affect NYHA Class in ATTR-CM patients according to BBIO's study?

The ATTRibute-CM study demonstrates that acoramidis improves NYHA Class at Month 30 compared to placebo in patients with ATTR-CM.